Cargando…
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer treatment. However, a large proportion of patients cannot benefit from it due to resistance or relapse, which is most likely attributable to the multiple immun...
Autores principales: | Wu, Yuze, Yi, Ming, Niu, Mengke, Mei, Qi, Wu, Kongming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513992/ https://www.ncbi.nlm.nih.gov/pubmed/36163047 http://dx.doi.org/10.1186/s12943-022-01657-y |
Ejemplares similares
-
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
por: Escors, David, et al.
Publicado: (2013) -
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
por: Wang, Yufei, et al.
Publicado: (2020) -
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022) -
Exploiting innate immunity for cancer immunotherapy
por: Yi, Ming, et al.
Publicado: (2023) -
Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
por: Qin, Guohui, et al.
Publicado: (2023)